Home › Decisions › AMPH 2026-02-24

AMPH FDA decision — Feb 24, 2026

✓ APPROVED

Amphastar Pharmaceuticals Inc. — Ipratropium Bromide HFA Inhalation Aerosol 1 · Bronchospasm associated with chronic obstructive p.

Run-up into the decision (T-120 → T+5)

Daily close, T-120 (9/9/25) through T+5. Run-up high $30.81 on 9/9/25, low $23.14 on 10/22/25 (T-120 to T-1). FDA decision 2/24/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-02-24

OutcomeApproved

Drug / candidateIpratropium Bromide HFA Inhalation Aerosol 1

CompanyAmphastar Pharmaceuticals Inc.

120-day run-up (T-120→T-1)-10.6%